OLIVA, STEFANIA
 Distribuzione geografica
Continente #
NA - Nord America 2.326
EU - Europa 1.835
AS - Asia 1.082
OC - Oceania 78
SA - Sud America 57
AF - Africa 18
Totale 5.396
Nazione #
US - Stati Uniti d'America 2.214
IT - Italia 882
CN - Cina 490
DE - Germania 153
SE - Svezia 149
JP - Giappone 137
SG - Singapore 130
GB - Regno Unito 118
IE - Irlanda 114
KR - Corea 87
CA - Canada 86
IN - India 78
FR - Francia 76
AU - Australia 70
VN - Vietnam 49
NL - Olanda 45
ES - Italia 41
FI - Finlandia 41
CH - Svizzera 31
ID - Indonesia 30
UA - Ucraina 30
BE - Belgio 28
BR - Brasile 26
MX - Messico 23
TR - Turchia 21
PL - Polonia 18
CO - Colombia 17
AT - Austria 15
DK - Danimarca 15
GR - Grecia 14
RU - Federazione Russa 14
PT - Portogallo 13
TH - Thailandia 11
HK - Hong Kong 10
HU - Ungheria 10
PK - Pakistan 10
IR - Iran 8
NZ - Nuova Zelanda 8
CL - Cile 7
TW - Taiwan 7
AR - Argentina 6
NO - Norvegia 6
CZ - Repubblica Ceca 5
IL - Israele 5
RO - Romania 5
ZA - Sudafrica 5
EG - Egitto 4
HR - Croazia 4
SN - Senegal 4
DZ - Algeria 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
BG - Bulgaria 2
PH - Filippine 2
SA - Arabia Saudita 2
UZ - Uzbekistan 2
CI - Costa d'Avorio 1
CU - Cuba 1
EC - Ecuador 1
GT - Guatemala 1
KZ - Kazakistan 1
MN - Mongolia 1
MY - Malesia 1
PA - Panama 1
TG - Togo 1
Totale 5.396
Città #
Florence 284
Chandler 169
Ashburn 163
Fairfield 133
Beijing 115
Dublin 111
Torino 104
Singapore 95
Wilmington 87
Houston 84
Woodbridge 82
Redwood City 76
Duncan 70
Nyköping 70
Seattle 65
Turin 60
Santa Clara 54
Cambridge 52
Tokyo 47
Dearborn 40
Ottawa 40
Shanghai 39
Ann Arbor 38
Medford 33
Guangzhou 32
Columbus 30
Hangzhou 30
Raritan 28
Princeton 27
Jakarta 26
Dong Ket 25
San Francesco 24
Perth 23
London 22
Nanjing 22
Villeurbanne 22
Jacksonville 21
New York 19
Milan 17
Rochester 16
Rome 16
Seoul 16
Campi Bisenzio 15
Changchun 15
Munich 15
Helsinki 14
Loma Linda 14
Wuhan 14
Noto 13
Pisa 13
Sydney 13
Boston 12
Fremont 12
Los Angeles 12
Nanchang 12
Vienna 12
Brussels 11
Chengdu 11
Baotou 10
Xian 10
Boardman 9
Padova 9
Pune 9
San Diego 9
Toronto 9
Budapest 8
Changsha 8
Hyderabad 8
San Mateo 8
São Paulo 8
Udine 8
Zhengzhou 8
Chennai 7
Hebei 7
Islamabad 7
Medellín 7
Ontario 7
Paris 7
Santiago 7
Bogotá 6
Hefei 6
Melbourne 6
Oxford 6
Taipei 6
Tianjin 6
Warsaw 6
Washington 6
Adelaide 5
Barcelona 5
Bologna 5
Chicago 5
Detroit 5
Düsseldorf 5
Forcoli 5
Fuzhou 5
Madrid 5
Moscow 5
Phoenix 5
San Jose 5
Tacoma 5
Totale 3.018
Nome #
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial 1.456
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma 798
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group 417
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives 235
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results 229
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis 194
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis 192
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 189
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis 176
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma 155
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial 145
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing 126
Promises and pitfalls in the use of PD-1/PD-L1 inhibitors in multiple myeloma 121
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma 109
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents 102
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. 89
Pursuing a curative approach in multiple myeloma: A review of new therapeutic strategies 89
Functional impact of genomic complexity on the transcriptome of Multiple Myeloma 85
Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives 77
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma 72
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study 65
Can the dismal prognosis of patients with central nervous system plasma cell neoplasms be improved? 65
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set 64
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. 59
Minimal Residual Disease in Multiple Myeloma: Ready for Prime Time? 52
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 50
Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials 36
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma 34
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma 27
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial 24
Predictors of Unsustained Minimal Residual Disease Negativity in Multiple Myeloma (MM) Patients 20
Evaluation of immunophenotyc and molecular profiles for Minimal residual disease assessment in multiple myelom: correlation with clinical features and outcome 6
Impact of daratumumab on collection and engraftment in multiple myeloma patients undergoing hematopoietic stem cell mobilization with G-CSF plus on-demand plerixafor 5
Totale 5.563
Categoria #
all - tutte 12.372
article - articoli 0
book - libri 0
conference - conferenze 399
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.771


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020567 0 0 0 0 57 63 48 47 129 91 85 47
2020/2021784 51 42 61 47 99 65 73 79 57 54 58 98
2021/2022856 55 61 37 102 56 43 39 57 39 75 149 143
2022/2023799 53 107 57 92 52 134 45 54 77 31 59 38
2023/2024583 55 76 38 60 37 86 55 39 3 43 19 72
2024/2025373 39 50 81 92 111 0 0 0 0 0 0 0
Totale 5.563